Breast Cancer

Encouraging results for Oncotype DX assay in predicting chemotherapy response

Published in Gene Therapy Weekly, July 8th, 2004

Genomic Health, Inc., and Istituto Nazionale Tumori, a cancer-research institute located in Milan, Italy, announced preliminary results of a clinical trial in which the patterns of expression of a substantial number of genes were clinically correlated to a pathologic complete response to chemotherapy.

The study also showed that the Oncotype DX Breast Cancer Assay Recurrence Score significantly correlated with response to chemotherapy in breast cancer patients. These results were presented at the annual meeting of the American Society of Clinical Oncology.

"We are encouraged by these early findings," said Luca Gianni, MD, Istituto Nazionale Tumori....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-07-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry